TD-0903

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903
Pharmaceutical Business Review
Fri, 06/26/20 - 09:42 am
Theravance
COVID-19
clinical trials
acute lung injury
TD-0903